StockData
MiNK Therapeutics, Inc. logo

MiNK Therapeutics, Inc. (INKT) stock

INKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$9.29−0.06 (-0.70%)

Close on Nov 17, 2026Market cap $47.38MP/E –Yield –

MiNK Therapeutics cash

Cash and short-term investments held at the end of each period.

MiNK Therapeutics's cash was $8.81M at Jun 30, 2026. For fiscal 2025 it was $13.36M, up 191.9% from the year before. The highest annual figure on record is $38.89M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$13.36M+191.9%
FY2024Dec 31, 2024$4.58M+35.9%
FY2023Dec 31, 2023$3.37M-82.9%
FY2022Dec 31, 2022$19.64M-49.5%
FY2021Dec 31, 2021$38.89M+1345.1%
FY2020Dec 31, 2020$2.69M+799.9%
FY2019Dec 31, 2019$299.04K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$8.81M+423.6%
Q1 FY2026Mar 31, 2026$9.53M+194.5%
Q4 FY2025Dec 31, 2025$13.36M+191.9%
Q3 FY2025Sep 30, 2025$9.50M+50.1%
Q2 FY2025Jun 30, 2025$1.68M-81.9%
Q1 FY2025Mar 31, 2025$3.23M-44.4%
Q4 FY2024Dec 31, 2024$4.58M+35.9%
Q3 FY2024Sep 30, 2024$6.33M-1.1%
Q2 FY2024Jun 30, 2024$9.31M-12.3%
Q1 FY2024Mar 31, 2024$5.82M-60.9%
Q4 FY2023Dec 31, 2023$3.37M-82.9%
Q3 FY2023Sep 30, 2023$6.40M-73.5%
Q2 FY2023Jun 30, 2023$10.62M-64.4%
Q1 FY2023Mar 31, 2023$14.89M-57.1%
Q4 FY2022Dec 31, 2022$19.64M-49.5%
Q3 FY2022Sep 30, 2022$24.16M+2848.1%
Q2 FY2022Jun 30, 2022$29.85M+1699.8%
Q1 FY2022Mar 31, 2022$34.69M+4181.1%
Q4 FY2021Dec 31, 2021$38.89M+1345.1%
Q3 FY2021Sep 30, 2021$819.45K-36.3%
Q2 FY2021Jun 30, 2021$1.66M+454.6%
Q1 FY2021Mar 31, 2021$810.27K–
Q4 FY2020Dec 31, 2020$2.69M–
Q3 FY2020Sep 30, 2020$1.29M–
Q4 FY2019Dec 31, 2019$299.04K–

More MiNK Therapeutics figures

See a number that looks wrong?